{
  "source": "PA-Med-Nec-Levemir.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2276-7\nProgram Prior Authorization/Medical Necessity\nMedication Levemir® (insulin detemir)*\nP&T Approval Date 7/2019, 7/2020, 8/2021, 2/2022, 5/2022, 6/2023, 6/2024\nEffective Date 9/1/2024\n1. Background:\nThe Endocrine Society recommends insulin NPH, an intermediate acting insulin, as the preferred\nbasal insulin in pregnancy. Patients may be switched to Levemir, a long-acting insulin, when\ntherapy with insulin NPH is inadequate. This program allows for coverage of Levemir for\npregnant patients when they have failed therapy with insulin NPH.\n2. Coverage Criteriaa,b:\nA. Levemir* will only be approved based on both of the following:\n1. Patient is pregnant\n-AND-\n2. History of failure, contraindication, or intolerance to insulin NPH\nAuthorization will be issued for 9 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb In Florida, Maine, and Tennessee only, medications prescribed for diabetes may be approved\nbased on both of the following: 1) Provider attests use of this product is medically necessary\nfor the treatment of diabetes; and- 2) If applicable, clinical characteristics exist that preclude\nthe use of the covered preferred alternative(s) and use of the covered preferred alternative(s)\ncould result in worsening of patient’s condition or inadequate treatment (document\nalternatives and clinical information related to worsening/inadequate treatment).\n* Levemir is typically excluded from coverage.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in",
    "revious claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Levemir [package insert]. Plainsboro, NJ: Novo Nordisk; December 2022.\n2. Ian Blumer, Eran Hadar, David R. Hadden, Lois Jovanovič, Jorge H. Mestman, M. Hassan\nMurad, Yariv Yogev, Diabetes and Pregnancy: An Endocrine Society Clinical Practice\nGuideline, The Journal of Clinical Endocrinology & Metabolism, Volume 98, Issue 11, 1\nNovember 2013, Pages 4227–4249.\n3. American Diabetes Association; Management of Diabetes in Pregnancy: Standards of Medical\nCare in Diabetes- 2023. Diabetes Care 2023;46 (Suppl. 1):S254-S266.\nProgram Prior Authorization/Medical Necessity - Levemir\nChange Control\n7/2019 New program.\n7/2020 Annual review. Updated references.\n8/2021 Annual review. Updated references.\n2/2022 Added Florida, Maine, and Tennessee mandate language.\nChanged program type from Non-Formulary (program number 1287) to\n5/2022\nMedical Necessity (program number 2276).\nAnnual review. Updated references. Updated diabetes state mandate\n6/2023\nlanguage.\n6/2024 Annual review. No changes.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}